On May 17, 2024, a jury trial in Delaware ruled that AstraZeneca Pharmaceuticals LP infringed upon a Pfizer-brand cancer treatment patent. As a result, they determined that AstraZeneca should pay $107.5 million in royalty damages. However, the final decision in this case will be deferred until following a bench trial specifically conducted to examine AstraZeneca’s additional defenses.
The case at hand sheds light on the rigorous landscape that characterizes patent rights in the pharmaceutical industry. Its outcome will thus inevitably have potential implications for copyright law and practice.
Please find a more detailed account of the proceedings and their fallout in this report, which situates the case within its broader legal and industrial context.